Related Experiment Video

Updated: May 7, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.2K

Impact of White Blood Cell Count After Percutaneous Coronary Intervention on Long-Term Prognosis in Patients with

Zhiyuan Zhang1,2,3, Heyan Wang4, Ruiyu Wang5

  • 1Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.

Vascular Health and Risk Management
|January 21, 2025
PubMed

Insights

Post-PCI leukocytosis in unstable angina patients predicts increased major adverse cardiovascular events (MACE) risk over 5 years. White blood cell and neutrophil counts rise, while lymphocyte counts decrease after percutaneous coronary intervention.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Biomarkers

Background:

  • Elevated white blood cell count (WBC-C) pre-PCI correlates with prognosis in patients undergoing percutaneous coronary intervention (PCI).
  • The impact of post-PCI WBC-C on long-term outcomes for unstable angina pectoris (UA) patients remains unclear.

Purpose of the Study:

  • To investigate the association between white blood cell count (WBC-C) after percutaneous coronary intervention (PCI) and the long-term prognosis in patients with unstable angina pectoris (UA).

Main Methods:

  • Retrospective cohort study of 1811 UA patients.
  • Analysis of WBC and subgroup counts pre- and post-PCI using paired Wilcoxon signed-rank test.
  • Kaplan-Meier method and COX regression to assess 5-year endpoint events and post-PCI leukocytosis.

Main Results:

  • Post-PCI leukocytosis and neutrocytosis were common; lymphocyte counts decreased.
  • No significant difference in 5-year all-cause mortality or MACCE between groups.
  • Significantly increased 5-year MACE incidence in the post-PCI leukocytosis group (p=0.017).
  • Post-PCI leukocytosis independently associated with MACE (HR 1.36, 95% CI 1.06-1.75, p=0.015).

Conclusions:

  • PCI increases peripheral WBC and neutrophil counts while decreasing lymphocyte counts in UA patients.
  • Post-PCI leukocytosis is a significant predictor of increased MACE risk up to 5 years in UA patients.
Abstract

Keywords:
leukocytosismajor adverse cardiovascular eventspercutaneous coronary interventionunstable angina pectoriswhite blood cell count

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.2K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.4K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...